✦ LIBER ✦

Neoplasia and the neuroleptic malignant syndrome

✍ Scribed by P. W. R. Wooduff; E. Palazidou; I. Cranston; B. K. Toone; B. Summers; A. L. W. F. Eddleston

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 309 KB
Volume: 6
Category: Article
ISSN: 0885-6222
DOI: 10.1002/hup.470060310

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The association of neuroleptic malignant syndrome with neoplasia has not been previously reported. We report the case of a 64‐year‐old female patient who developed the classical picture of neuroleptic malignant syndrome in relation to a uterine leiomyosarcoma. This raises the question as to whether a biological predisposition exists in patients who develop neuroleptic malignant syndrome.

📜 SIMILAR VOLUMES

Neuroleptic malignant syndrome: Mechanis

Neuroleptic malignant syndrome: Mechanisms, interactions, and causality

✍ P. Ken Gillman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

## Abstract This review focuses on new data from recent publications concerning how compounding interactions between different thermoregulatory pathways influence the development of hyperthermia and/or neuroleptic malignant syndrome (NMS), and the fundamental issue of the presumed causal role of an

Clinical risk factors for neuroleptic ma

Clinical risk factors for neuroleptic malignant syndrome

✍ Domenico Berardi; Maddalena Dell'Atti; Mario Amore; Diana De Ronchi; Giuseppe Fe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB

Pharmacological risk factors for neuroleptic malignant syndrome (NMS) are better defined than clinical risk factors. We examined the psychopathological status preceding the onset of NMS in 20 patients. We evaluated four key psychiatric symptoms (psychomotor agitation, catatonia, disorganization and

Treatment of neuroleptic malignant syndr

Treatment of neuroleptic malignant syndrome with levodopa

✍ K. Otani; K. Mihara; T. Kondo; M. Okada; S. Kaneko; Y. Fukushima 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 400 KB

Seven consecutive episodes of neuroleptic malignant syndrome in five cases were treated with 50-600 mg/day (mean 342 mg/day) of levodopa. In four episodes active pharmacological treatment was initiated with levodopa, while in the remaining three episodes it was introduced because of poor therapeutic

Normal neuropathological findings after

Normal neuropathological findings after neuroleptic malignant syndrome

✍ Hannu J. Koponen; Ulla Lepola; Esa Leinonen; Leo Paljärvi 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB

Neuroleptic malignant syndrome (NMS) is a rare, life-threatening complication of antipsychotic drug treatment. Its pathophysiology is controversial, and the same is true for the findings in post-mortem studies on central nervous system pathology. In this report we present a patient who died two and

Neuroleptic malignant-like syndrome indu

Neuroleptic malignant-like syndrome induced by metoclopramide

✍ Dr. M. Reza Samie 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 275 KB

A prompt recognition of neuroleptic malignant-like syndrome is essential because of its high morbidity and mortality. A similar condition is described associated with metoclopramide, an agent with dopamine receptorblocking properties. An increased index of suspicion for early diagnosis of this condi

Hyperglycemia as a symptom of neurolepti

Hyperglycemia as a symptom of neuroleptic malignant syndrome

✍ M. Ishida; K. Otani; S. Kaneko; H. Ishida; S. Kawashima 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB

A 67-year-old schizophrenic woman developed neuroleptic malignant syndrome (NMS). She had mild diabetes mellitus, which had been controlled with diet therapy only. Upon the onset of NMS, hyperglycemia of up to 490 mg/dl developed. The hyperglycemia persisted during the NMS episode despite insulin tr